Brought to you by 
Meristem Therapeutics, Quintiles form alliance
22 Jun 2022
Executive Summary
Meristem Therapeutics (recombinant protein development) will combine its Genie Vegetal plant engineering technology with Quintiles' (CRO) product development expertise to assist pharmaceutical and biotechnology companies with the development of therapeutic proteins.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Meristem Therapeutics, Quintiles form alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice